|
|
Leadership
|
| Winston
Ko, MBA |
CEO,
Chairman of Board |
| Dorothy
Ko, MS |
COO |
| Raymond
Chau, PhD |
Chief
Scientist |
| Mark Kindy, Ph.D. |
Research Scientist |
| Frank
Young, MD |
Regulatory
Advisor |
| PC
Chan-Yu, PhD |
Clinical
Research |
| Tony
Shum, MD |
Clinical
Research |
| Frank
Han, MD |
Medical
Officer |
| Lorraine DeCesare, RPh |
Clinical Trial Manager |
| James
Collett, Esq. |
Patent
Legal |
| Kristen
Lemme |
Patent |
|
|
In addition Genervon employs over 100 consultants,
specialists and contract research organizations. The company is focused
on streamlining the drug development process as much as possible
through the use of contract research organizations (CROs). This
strategy offers the benefits of fast delivery, higher levels of
efficiency as well as lowered costs associated with drug development.
|
|
